Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Wong ND, Fan W, Philip S, et al. REDUCE-IT eligibility and preventable cardiovascular events in the US population (from the National Health and Nutrition Examination Survey [NHANES]). Am J Cardiol. 2020; epub ahead of print.

https://www.ajconline.org/article/S0002-9149(20)30861-4/fulltext
Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial).

Nelson AJ, Navar A, Mulder H, Wojdyla D, Philip S, Granowitz C, Peterson ED, Pagidipati NJ. Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial). Am J Cardiol. 2020; epub ahead of print.

Toth P, Granowitz C, Hull M, Philip S. Elevated triglycerides and atherosclerotic cardiovascular disease are significant predictors of major cardiovascular events and increased health care costs in statin-treated patients: a real-world analysis. J Manag Care Spec Pharm. 2018;24(4 suppl a):S70-S71.

https://www.jmcp.org/doi/pdf/10.18553/jmcp.2018.24.4-a.s1

Toth P, Granowitz C, Hull M, Philip S. Long-term statin persistence is poor among high-risk patients with baseline peripheral artery disease: a real-world administrative claims analysis of the Optum research database [abstract]. J Am Coll Cardiol. 2019;73:1744.

http://www.onlinejacc.org/content/73/9_Supplement_1/1744
Leatherman S, Ferguson R, Weir I, et al. Increased residual cardiovascular risk in US veterans and moderately-elevated baseline triglycerides and well-controlled LCL-C levels on statins [abstract]. J Am Coll Cardiol. 2019;73:1719. http://www.onlinejacc.org/content/73/9_Supplement_1/1719

Toth P, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. Long-term renal function worsens in high cardiovascular risk patients with high triglycerides and well-controlled low-density lipoprotein cholesterol in a real-world analysis [abstract]. J Am Coll Cardiol. 2018;71(11 suppl):A1445.

http://www.onlinejacc.org/content/71/11_Supplement/A1445

Pagidipati N, Navar A, Mulder H, Wojdyla DM, Philip S, Granowitz CB. Association between triglycerides and residual cardiovascular (CVD) risk in patients with type 2 diabetes and established CVD: an analysis of the BARI2D trialDiabetes. 2019;68(suppl 1):1472P.

http://diabetes.diabetesjournals.org/content/68/Supplement_1/1472-P

Toth PP, Philip S, Hull M, Granowitz C. Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dL) are significant predictors of new heart failure diagnosis: A real-world analysis of high-risk statin-treated patients. Vasc Health Risk Manag. 2019;15:533-538.

https://www.ncbi.nlm.nih.gov/pubmed/31824165

Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk By Statin Use In U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014. Diabetes Care. 2019. [Epub ahead of print]

https://care.diabetesjournals.org/content/early/2019/09/27/dc19-0501

Gitt AK. Prevalence Of Hypertriglyceridaemia In Statin Treated Very High-Risk Patients Who Might Benefit From Treatment With Icosapent Ethyl For Secondary Prevention In Clinical Practice–Results Of DYSIS. EMJ Cardiol. 2019;7:61-62.

https://emj.emg-health.com/wp-content/uploads/sites/2/2019/10/Icosapent-Ethyl-for-the-Prevention-of-Cardiovascular-Events.pdf

In Chronological Order

 

Vijayaraghavan K, Szerlip HM, Ballantyne CM, Bays HE, Philip S, Doyle RT, Juliano RA, Granowitz C. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Postgrad Med. 2019; epub ahead of print. https://www.tandfonline.com/doi/full/10.1080/00325481.2019.1643633

https://www.ncbi.nlm.nih.gov/pubmed/31306043

Toth PP, Philip S, Hull M, Granowitz C. Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patientsMayo Clin Proc. 2019;94(9):1670-1680.
https://www.mayoclinicproceedings.org/article/S0025-6196(19)30382-9/fulltext

https://www.ncbi.nlm.nih.gov/pubmed/31405751

Toth PP, Philip S, Hull M, Granowitz C. Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dL) are significant predictors of hospitalization for new-onset kidney disease: a real-world analysis of high-risk statin-treated patientsCardiorenal Med. 2019.

https://www.ncbi.nlm.nih.gov/pubmed/31450229

Toth PP, Philip S, Hull M, Granowitz C. Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysisClin Cardiol. 2019;1–6.

https://doi.org/10.1002/clc.23241

Picard F, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG. Generalizability of the REDUCE-IT trial in patients with stable coronary artery diseaseJ Am Coll Cardiol. 2019;73:1362-1364.
https://www.ncbi.nlm.nih.gov/pubmed/30819552

https://www.sciencedirect.com/science/article/pii/S0735109719302736?via%3Dihub=
copyright
© 2021, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
Spaces South Docklands
Block C
77 Sir John Rogerson's Quay
Dublin 2, D02 VK60
Investor Relations
AMARIN CORPORATION PLC C/O AMARIN PHARMA, INC.
440 ROUTE 22
BRIDGEWATER, NJ 08807
investor.relations@amarincorp.com
Fax:
+1 908 719 3012

Amarin Corporation